University of Vermont

College of Medicine

Department of Medicine

Infectious Disease

Bio for Mary Ramundo, M.D.
Mary Ramundo, M.D.

Mary Ramundo, M.D.

Associate Professor of Medicine, Infectious Disease Medicine
Department of Medicine


Contact Information
E-mail: Mary.Ramundo@uvm.edu
Office Location:
Medicine, Smith, Rm 272

Education

1976-1980 B.A. (Biology), Colby College Waterville, Maine
1982-1986 M.D., UMDNJ-Rutgers Medical School Piscataway, New Jersey
1986-1987 Intern, Internal Medicine The Cornell Hospitals Program B North Shore University Hospital Manhasset, New York
1987-1989 Resident, Internal Medicine The Cornell Hospitals Program B North Shore University Hospital Manhasset, New York

Academic Appointments

July 2001 - present Associate Professor of Medicine University of Vermont Burlington, Vermont
July 1995- 2001 Assistant Professor of Medicine
December 1994-June 1995 Associate, Infectious Disease Geisinger Medical Center Danville, Pennsylvania
July 1991-November 1994 Assistant Professor of Internal Medicine The Ohio State University Columbus, Ohio
1989-1991 Fellow, Internal Medicine Cornell University Medical College New York, New York
1987-1989 Clinical Associate, Internal Medicine Cornell University Medical College New York, New York

Research Grants

Multicenter, Double Blind, placebo Controlled, Randomized, Phase 3 Study of tifacogain ( Recombinant Tissue Pathway Inhibitor ( rTFPI/59735 ) in Severe Sepsis. Chiron, rTFPI/59735, 6/00 – present, PI: WK Alston.

Evaluation of the Viral Profile and Symptoms in Patients with Infectious Mononucleosis. Upjohn, 672-INF-0500-001, PI: M. Ramundo.

The Norvir/Indinavir Combination Evaluation Study: A Randomized, Controlled, Open-Label Comparison of Continuing Indinavir Q8H vs. Switching to Norvir/Indinavir 400mg/400mg BID. Abbott Laboratories, M99-047, 10/99 – 9/00, PI: M.Ramundo.

Title III Ryan White Care Act Grant for HIV Care. Health Resource Service Administration, 1998 – 2001, $ 1,200,000, PI: C. Grace, Co-investigator: M.Ramundo.

Title II Ryan White Care Grant for HIV Care. Vermont Department of Health, 1998 –2001, $120,000, PI: C.Grace.

An Open-label Randomized Study of Delavirdine mesylate (DLV) in Triple and Quadruple Combinations with Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals. Upjohn, M/3331/0074, 10/97 – 2/00, PI: CJ Grace, Co-investigator: M Ramundo.

An Open-label Randomized Study of Delavirdine mesylate (DLV) plus Nelfinavir (NFV), Didanosine (ddI), and Stavudine (d4T) in Triple and Quadruple Treatment Regimens in HIV-1 Infected Individuals. Upjohn, M/3331/0073, 10/97 – 2/00, PI: CJ Grace, Co-investigator: M Ramundo.

Linezolid ( PNU-10766 ) in the Treatment of Gram Positive Bacteremia: An Open Label Phase II Study of Intravenous Therapy with Optional Oral Continuation. Upjohn, M/1260/0011, 10/97 – 8/98, PI: WK Alston, Co-investigator: M Ramundo.

A Multicenter, Double-Blind, Randomized Placebo-controlled Study of Filgrastin in the Treatment of Patients with Multilobar Pneumonia. Amgen, GCSF 950273, 3/97, PI: CJ Grace, Co-investigator: M Ramundo.

U100766 in Treatment of Skin/Soft Tissue Infections: An Open Label, Dose Comparative Phase II Study of Intravenous Therapy with Optional Oral Continuation. Upjohn, M/1260/0010, 7/96 - 98, PI: CJ Grace, Co-investigator: MB Ramundo.

U100766 in Treatment of Community Acquired Streptococcus pneumoniae Pneumonia: An Open Label, Dose Comparative Phase II Study of Intravenous Therapy with Optional Oral Continuation. Upjohn, M/1260/0009, 7/96 - 98, PI: CJ Grace, Co-investigator: MB Ramundo.

Prospective, Double-Blind, Placebo-Controlled, Randomized, Multicenter North American Study of the Safety and Efficacy of Murine Monoclonal Antibody to Tumor Necrosis Factor for the Treatment of Patients with Septic Shock. Bayer, 587-9201, 3/94 – 2/97, PI: WK Alston, Co-investigator: MB Ramundo.

A Double-Blind, Randomized, Combination Therapy Trial of Delavirdine ( DLV ) and Zidovudine ( ZDV ) and Lamivudine ( 3TC ) versus DLV and ZDV and 3TC as Initial Therapy of Following Part I Therapy in HIV-1 Infected Individuals with CD4 Counts of 200-500/mm3 (Part II ). Upjohn, M/3331/0021, 9/17/93 – 8/98, PI: CJ Grace, Co-investigator: MB Ramundo.

Rural HIV Service Delivery Models. Health Resource Service Administration, 10/94-9/98, $ 1,500,000, PI: CJ Grace, Co-investigator: MB Ramundo.

A Randomized, Double-blind, Multicenter, Parallel Study of HIV Proteinase Inhibitor Alone, Zalcitabine (ddC) Alone, and Both in Combination as Treatment for Advanced HIV Infection in Patients Discontinuing or Unable to take Zidovudine Therapy. Hoffmann-LaRoche, NV14256, 06/01/94 - 5/31/95. $162,767, PI: MB Ramundo.

A Randomized, Open-label Study of Alternative Treatment Combinations of Dideoxycytidine (ddC) and Zidovudine (ZDV) in Patients with HIV Infection. Hoffmann-LaRoche, Inc., NV 14257, 05/01/93 - 06/01/95. $220,712, PI: MB Ramundo.

Prospective Study Comparing Plasma PCR and Viral Culture for the Detection of CMV Viremia as a Predictor of Invasive CMV Disease. The Ohio State University Seed Grant Program, 221552, 12/31/92 - 06/30/94. $19,186, PI: MB Ramundo.

Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG). National Institutes of Allergy and Infectious Diseases, 5 UOI AI25924, 04/01/92-01/31/96; $7,303,256, PI: RJ Fass, Co-investigator: MB Ramundo.

Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG). National Institutes of Allergy and Infectious Diseases, 1 UO1 AI25924, 09/01/87-03/31/92, $7,284,485, PI: R.J. Fass, Co-investigator: MB Ramundo.

Awards and Honors

1979, 1980 Charles A. Dana Scholarship for academic achievement and potential leadership.
1980 Alan Samuel Coit Biology Prize for meritorious achievement in biology.
1980 Graduated Magna Cum Laude
1980 Phi Beta Kappa
1985 Alpha Omega Alpha
1991 George M. Jaffin Department of Medicine Scholarly Activity Award

Publications

Ciobotaru B, Leiman G, St John T, Hyman N, Ramundo M, Grace C. Prevalence and resk factors for anal cytologic abnormalities and human papillomavirus infection in a rural population of HIV infected males. Disease of the Colon & Rectum 2007;50(7):1011-6

Applebee A, Ramundo M, Kirkpatrick BD, Fries TJ, Panitch H. Intramedullary spinalcord abscess in  a healthy woman. Neurology 2007;68(15):1230

Rathmell JP, Lake T, Ramundo MD. Infectious risks of chronic pain treatments: injection therapy, surgical implants, and intradiscal techniques. Reg Anesth & Pain Med. 2006;31(4):346-52

Ramundo MB, Farber BF. HIV Infection and Critical Care. In: Pinsky MR, Dhainaut JA, ed. Pathophysiologic Foundations of Critical Care Medicine. Baltimore: Williams & Wilkins. 1992; 851-862.

Ramundo MB, Farber BF. Antibiotics Available to Treat Methicillin-Resistant Staphylococcus aureus. In: Cafferkey M, ed. Methicillin-Resistant Staphylococcus aureus: Clinical Management and Laboratory Aspects. New York: Marcel Dekker, Inc. 1992; 107-124.